Secondary malignant neoplasm of left kidney and renal pelvis
ICD-10 C79.02 is a billable code used to indicate a diagnosis of secondary malignant neoplasm of left kidney and renal pelvis.
C79.02 refers to a secondary malignant neoplasm located in the left kidney and renal pelvis, indicating that the cancer has metastasized from another primary site to this specific location. This condition is characterized by the presence of malignant cells in the kidney and renal pelvis, which can arise from various primary cancers, such as lung, breast, or colorectal cancers. The diagnosis of a secondary malignant neoplasm typically occurs after the identification of the primary cancer, which may not always be known at the time of diagnosis. Staging of the disease is crucial, as it helps determine the extent of metastasis and guides treatment options. Palliative care considerations are essential for managing symptoms and improving the quality of life for patients with advanced metastatic disease. Treatment may include chemotherapy, radiation therapy, or targeted therapies, depending on the primary cancer type and the patient's overall health status. Accurate coding of this condition is vital for appropriate reimbursement and to ensure that patients receive the necessary care.
Comprehensive documentation of the primary cancer, staging, and treatment plans.
Patients presenting with metastatic disease from known primary cancers, requiring chemotherapy or radiation.
Ensure accurate documentation of the metastatic site and any palliative care measures implemented.
Detailed reports of imaging studies, biopsy results, and surgical interventions.
Patients with renal masses undergoing evaluation for metastatic disease.
Documentation must clearly differentiate between primary renal tumors and secondary neoplasms.
Used when a biopsy of the renal mass is performed to confirm metastatic disease.
Pathology report must indicate the presence of malignant cells and their origin.
Oncologists and pathologists must collaborate to ensure accurate diagnosis.
Accurate coding of C79.02 is crucial for appropriate reimbursement, ensuring that patients receive the necessary care for metastatic disease, and for maintaining accurate cancer registries.
